JJBC
ABBV icon

James J. Burns & Company’s AbbVie ABBV Stock Holding History

James J. Burns & Company’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$442K Sell
1,756
-69
-4% -$14.8K 0.05% 110
2026
Q1 		$397K Sell
1,825
-20
-1% -$4.44K 0.05% 105
2025
Q4 		$422K Sell
1,845
-20
-1% -$4.56K 0.06% 104
2025
Q3 		$432K Sell
1,865
-39
-2% -$7.94K 0.06% 101
2025
Q2 		$353K Sell
1,904
-102
-5% -$19K 0.06% 108
2025
Q1 		$420K Buy
2,006
+240
+14% +$46.7K 0.08% 93
2024
Q4 		$313K Buy
1,766
+397
+29% +$73K 0.05% 110
2024
Q3 		$270K Sell
1,369
-88
-6% -$16.4K 0.05% 118
2024
Q2 		$250K Buy
1,457
+119
+9% +$19.7K 0.05% 112
2024
Q1 		$242K Sell
1,338
-75
-5% -$12.9K 0.08% 78
2023
Q4 		$219K Sell
1,413
-213
-13% -$31.1K 0.05% 112
2023
Q3 		$242K Buy
+1,626
New +$239K 0.07% 93
2023
Q2 		– Sell
-1,489
Closed -$237K – 114
2023
Q1 		$237K Buy
1,489
+124
+9% +$19K 0.06% 102
2022
Q4 		$221K Buy
+1,365
New +$209K 0.09% 75

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

James J. Burns & Company's ABBV Position: Q2 2026 in Review

James J. Burns & Company reduced its AbbVie (ABBV) stake by 3.8% in Q2 2026, selling an estimated $14.8K and leaving 1,756 shares worth $442K. The position accounts for 0.05% of the portfolio, ranked #110.

James J. Burns & Company first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • James J. Burns & Company held 1,756 shares of AbbVie worth $442K as of Q2 2026.
  • James J. Burns & Company sold 69 AbbVie shares in Q2 2026, an estimated $14.8K.
  • AbbVie made up 0.05% of James J. Burns & Company's portfolio in Q2 2026, its #110 holding.
  • James J. Burns & Company first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on James J. Burns & Company's 13F filing for Q2 2026, filed 6 Aug 2026.